GlassScriptPhysician profile
Benjamin O Dahunsi
NPI 1225535206
$4,775.30
in general payments reported to CMS, 2019-2025
20 companies · $635 in 2025
The $635 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $971 · 2023: $1,966 · 2024: $1,203 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,803.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $642.35 | 2022-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $615.08 | 2022-2025 | Caplyta |
| Abbvie INC. | $601.61 | 2022-2025 | |
| Corium, LLC | $453.82 | 2022-2024 | Azstarys |
| Lundbeck LLC | $439.43 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Almatica Pharma LLC | $348.49 | 2023-2025 | Loreev Xr |
| Alkermes, INC. | $316.92 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $228.63 | 2024-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $180.25 | 2023-2024 | Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $176.42 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $144.54 | 2023-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $135.24 | 2024-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $99.40 | 2022 | |
| Supernus Pharmaceuticals, INC. | $95.56 | 2022-2024 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $89.67 | 2024-2025 | Cobenfy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $60.04 | 2023-2024 | Quviviq |
| Indivior INC. | $50.35 | 2022-2023 | Sublocade |
| Ironshore Pharmaceuticals INC. | $37.48 | 2024 | |
| Vanda Pharmaceuticals INC. | $35.20 | 2024 | Hetlioz, Fanapt |
| Bausch Health US, LLC | $24.82 | 2023 | Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Dahunsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.